NRX PHARMACEUTICALS INC

NASDAQ: NRXP (NRX Pharmaceuticals, Inc.)

Last update: 6 days ago, 1:03AM

3.48

-0.17 (-4.66%)

Previous Close 3.65
Open 3.70
Volume 276,132
Avg. Volume (3M) 251,180
Market Cap 60,166,416
Price / Book 2.90
52 Weeks Range
1.10 (-68%) — 6.01 (72%)
Earnings Date 12 Aug 2025 - 18 Aug 2025
Diluted EPS (TTM) -2.36
Current Ratio (MRQ) 0.150
Operating Cash Flow (TTM) -10.64 M
Levered Free Cash Flow (TTM) -3.99 M
Return on Assets (TTM) -224.60%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock NRX Pharmaceuticals, Inc. Bullish Bearish

AIStockmoo Score

1.8
Analyst Consensus 5.0
Insider Activity NA
Price Volatility -4.5
Technical Moving Averages 2.5
Technical Oscillators 4.0
Average 1.75

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NRXP 60 M - - 2.90
PTCT 4 B - 7.87 -
CRNX 3 B - - 2.40
VRDN 1 B - - 3.12
KALV 648 M - - 4.61
VERV 569 M - - 1.15

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 17.08%
% Held by Institutions 6.20%

Ownership

Name Date Shares Held
Townsquare Capital Llc 31 Mar 2025 15,041
One Wealth Management Investment & Advisory Services, Llc 31 Mar 2025 15,041
52 Weeks Range
1.10 (-68%) — 6.01 (72%)
Price Target Range
18.00 (417%) — 46.00 (1221%)
High 46.00 (Ascendiant Capital, 1,221.84%) Buy
Median 25.00 (618.39%)
Low 18.00 (BTIG, 417.24%) Buy
Average 28.50 (718.97%)
Total 4 Buy
Avg. Price @ Call 2.35
Firm Date Target Price Call Price @ Call
D. Boral Capital 06 Jun 2025 31.00 (790.80%) Buy 3.27
16 May 2025 31.00 (790.80%) Buy 2.45
Ascendiant Capital 29 Apr 2025 46.00 (1,221.84%) Buy 2.06
BTIG 02 Apr 2025 18.00 (417.24%) Buy 2.01
HC Wainwright & Co. 20 Mar 2025 19.00 (445.98%) Buy 2.07

No data within this time range.

Date Type Details
16 Jun 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
16 Jun 2025 Announcement New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST
14 Jun 2025 Announcement New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
12 Jun 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
05 Jun 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine
05 Jun 2025 Announcement New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
21 May 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida
15 May 2025 Announcement HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
15 May 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update
13 May 2025 Announcement HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics
12 May 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025
06 May 2025 Announcement HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
05 May 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine
30 Apr 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression
21 Apr 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
03 Apr 2025 Announcement HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
31 Mar 2025 Announcement HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics
24 Mar 2025 Announcement HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics
17 Mar 2025 Announcement NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria